Pfizer Inc. (NYSE:PFE) Shares Sold by Bridgeworth LLC
Bridgeworth LLC reduced its holdings in Pfizer Inc. (NYSE:PFE) by 2.0% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 17,245 shares of the biopharmaceutical company’s stock after selling 359 shares during the quarter. Bridgeworth LLC’s holdings in Pfizer were worth $620,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also bought and sold shares of the company. Evolution Wealth Advisors LLC acquired a new position in Pfizer during the second quarter worth $34,000. IMA Wealth Inc. raised its holdings in Pfizer by 144.5% during the second quarter. IMA Wealth Inc. now owns 807 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 477 shares during the last quarter. Financial Gravity Wealth Inc. raised its holdings in Pfizer by 33.2% during the second quarter. Financial Gravity Wealth Inc. now owns 1,031 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 257 shares during the last quarter. Vestor Capital LLC raised its holdings in Pfizer by 60.1% during the second quarter. Vestor Capital LLC now owns 1,547 shares of the biopharmaceutical company’s stock worth $67,000 after purchasing an additional 581 shares during the last quarter. Finally, Global Trust Asset Management LLC raised its holdings in Pfizer by 346.4% during the second quarter. Global Trust Asset Management LLC now owns 7,758 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 6,020 shares during the last quarter. 71.70% of the stock is owned by institutional investors and hedge funds.
Several equities analysts have weighed in on the company. ValuEngine raised Pfizer from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. UBS Group reissued a “neutral” rating and set a $43.00 price target on shares of Pfizer in a research report on Monday, August 5th. Zacks Investment Research raised Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price target for the company in a research report on Tuesday, October 1st. JPMorgan Chase & Co. raised their price target on Pfizer from $37.00 to $46.00 and gave the stock a “neutral” rating in a research report on Thursday, September 19th. They noted that the move was a valuation call. Finally, Credit Suisse Group reissued a “neutral” rating on shares of Pfizer in a research report on Monday, August 12th. Twelve analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Pfizer has a consensus rating of “Hold” and a consensus price target of $45.20.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Monday, July 29th. The biopharmaceutical company reported $0.80 EPS for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.05. The business had revenue of $13.26 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 28.10% and a net margin of 23.58%. The business’s revenue for the quarter was down 1.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.77 earnings per share. Equities research analysts predict that Pfizer Inc. will post 2.81 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a $0.36 dividend. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.93%. The ex-dividend date of this dividend is Thursday, November 7th. Pfizer’s dividend payout ratio is currently 48.00%.
In other Pfizer news, major shareholder Pfizer Inc acquired 50,000 shares of the stock in a transaction dated Tuesday, September 17th. The stock was acquired at an average price of $18.00 per share, with a total value of $900,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Scott Gottlieb acquired 3,000 shares of the stock in a transaction dated Friday, August 23rd. The stock was acquired at an average cost of $34.72 per share, with a total value of $104,160.00. Following the transaction, the director now owns 3,000 shares of the company’s stock, valued at $104,160. The disclosure for this purchase can be found here. 0.09% of the stock is owned by insiders.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Featured Article: Understanding Compound Annual Growth Rate (CAGR)
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.